Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma

作者：Xin Liu, Tao Wu, Su-Yu Zhu, Mei Shi, Hang Su, Ying Wang, Xia He, Liming Xu, Zhiyong Yuan, Liling Zhang, Gang Wu, Baolin Qu, Li-Ting Qian, Xiao-Rong Hou, Fu-Quan Zhang, Yu‐Jing Zhang, Yuan Zhu, Jian-Zhong Cao, Shengmin Lan, Jun-Xin Wu, Shu‐Nan Qi, Yong Yang, Ye‐Xiong Li · 发表于：JAMA Network Open · 年份：2019 · DOI：10.1001/jamanetworkopen.2019.0194 · 被引用次数：48 · 研究领域：Lymphoma Diagnosis and Treatment、CNS Lymphoma Diagnosis and Treatment、Cutaneous lymphoproliferative disorders research

Importance: Prognosis of early-stage extranodal natural killer/T-cell lymphoma (NKTCL) is usually estimated and stratified at diagnosis, but how the prognosis actually evolves over time for patients who survived after curative treatment is unknown. Objective: To assess conditional survival and failure hazard over time based on risk categories, previous survival, and treatment. Design, Setting, and Participants: This retrospective cohort study reviewed the clinical data of 2015 patients with early-stage NKTCL treated with radiotherapy identified from the China Lymphoma Collaborative Group multicenter database between January 1, 2000, and December 31, 2015. Patients were stratified into low-, intermediate- and high-risk groups according to a previously established prognostic model. Median follow-up was 61 months for surviving patients. Data analysis was performed from December 1, 2017, to January 30, 2018. Exposures: All patients received radiotherapy with or without chemotherapy. Main Outcomes and Measures: Conditional survival defined as the survival probability, given patients have survived for a defined time, and annual hazard rates defined as yearly event rate. Results: A total of 2015 patients were included in the study (mean [SD] age, 43.3 [14.6] years; 1414 [70.2%] male); 1628 patients (80.8%) received radiotherapy with chemotherapy, and 387 (19.2%) received radiotherapy without chemotherapy. The 5-year survival rates increased from 69.1% (95% CI, 66.6%-71.4%) at treatm...